Kazia Therapeutics Limited

NASDAQ (USD): Kazia Therapeutics Limited (KZIA)

Last Price

3.02

Today's Change

-0.07 (2.26%)

Day's Change

2.88 - 3.16

Trading Volume

59,669

Profile
KZIA

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. John Edwin Friend II, M.D. Dr. John Edwin Friend II, M.D.

Full Time Employees:  9 9

IPO Date:  1999-01-06 1999-01-06

CIK:  0001075880 0001075880

ISIN:  US48669G1058 US48669G1058

CUSIP:  48669G105 48669G105

Beta:  2.08 2.08

Last Dividend:  0.00 0.00

Dcf Diff:  4.96 4.96

Dcf:  0.12 0.12

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Address

Three International Towers,
Sydney, NSW 2000, AU

1300 787 272

http://www.kaziatherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment